Get started Log in

KRRO — Korro Bio Share News

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Market Cap
$177.44m
Enterprise Value
$62.41m
Revenue
$6.39m

U.S. STOCKS ON THE MOVE-Canopy Growth, Ero Copper, VerifyMe,
14/07/2023 19:11
U.S. STOCKS ON THE MOVE-AT&T, Caribou Biosciences, housing stocks
14/07/2023 17:07
U.S. STOCKS ON THE MOVE-Netflix, Microsoft, AT&T
14/07/2023 14:21
U.S. STOCKS ON THE MOVE-Activision Blizzard, UnitedHealth Group, Nikola
14/07/2023 12:48
Frequency Therapeutics jumps on merger agreement with Korro Bio
14/07/2023 11:57
Brief: Frequency Therapeutics To Reduce About 55% Workforce
06/06/2023 21:53
Frequency Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
12/05/2023 21:49
Brief: Frequency Therapeutics Provides Business Updates And First Quarter 2023 Financial Results
12/05/2023 21:03
Frequency Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
29/04/2023 03:11
Brief: Frequency Therapeutics Receives Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
29/03/2023 22:02
Frequency Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
13/03/2023 12:31
Brief: Frequency Therapeutics Provides Business Updates And Fourth Quarter And Full Year 2022 Financial Results
10/03/2023 12:33
Frequency Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
10/03/2023 12:30
U.S. RESEARCH ROUNDUP- Arista Networks, Dominion Energy, TransDigm Group
14/02/2023 07:14
Frequency Therapeutics hits record low on plan to stop hearing treatment programs
13/02/2023 16:38
Frequency Therapeutics slumps on layoffs, plan to stop hearing loss treatment programs
13/02/2023 14:18
Brief: Frequency Therapeutics Announces Topline Results For Its Phase 2B Study Of FX-322
13/02/2023 13:25
Brief: Frequency Therapeutics Announces Formation Of Clinical Advisory Board For Remyelination In Multiple Sclerosis Program
19/12/2022 12:32
Brief: Frequency Therapeutics Announces First Patient Dosed In Phase 1B Study Of FX-345, Its Second Therapeutic Candidate For Sensorineural Hearing Loss
15/12/2022 12:45
Brief: Frequency Therapeutics Inc Reports Q3 Loss Per Share Of $0.55
08/11/2022 21:26